Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial

Jena, Monalisa; Ranjan, Rajeev; Mishra, Biswa Ranjan; Mishra, Archana; Nath, Santanu; Sahu, Pallabi; Meher, Bikash Ranjan; Srinivasan, Anand; Maiti, Rituparna

doi:10.1016/j.jpsychires.2019.02.007

Cited by 20 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have enrolled firstepisode drug-naive patients with schizophrenia (the same as the present study) and indicated that the serum levels of NGF were not associated with the PANSS total or subscale scores. 19,45 A possible explanation for the nominal association for NGF in the present study may be that the serum levels of NGF may be correlated with symptom severity only in certain subtypes of schizophrenia (for example, the negative group in the present study). In addition, it cannot be PCN Psychiatry and…”

Section: Discussionmentioning

confidence: 57%

“…21 After treatment, increases in serum levels of NGF and NT-3 were reported in schizophrenia. 45 Thus, the different types of schizophrenia patients (drug-naive or medicated) collected in studies may contribute to the discrepancies in results. NGF and NT-3 belong to the neurotrophin family and a growing body of evidence supports that neurotrophic system deficits in cortical neurons play an important role in the pathophysiology of schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Different serum protein factor levels in first‐episode drug‐naive patients with schizophrenia characterized by positive and negative symptoms

Dai

Jie

Duan³

et al. 2020

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aim The clinical features of schizophrenia can be mainly divided into two symptom domains: positive and negative. Patients in each symptom domain respond differently to treatments, and their prognoses vary accordingly. Serum protein factors, such as nerve growth factor (NGF), neurotrophin‐3 (NT‐3), interleukin‐6 (IL‐6), interleukin‐1 beta (IL‐1β), and the calcium‐binding protein, S100β, have been reported to be involved in the pathogenesis of schizophrenia. However, their roles in the positive and negative symptom domains have not been determined. In this study, we investigated whether the serum levels of these five protein factors differed among first‐episode drug‐naive schizophrenia patients in each symptom domain and in healthy controls. Methods Double‐antibody sandwich ELISA were used to quantify the amounts of the five protein factors in serum. Results Compared with the levels in the controls (n = 60), increased serum levels of IL‐6, IL‐1β, and S100β and decreased serum levels of NGF and NT‐3 were observed in first‐episode drug‐naive schizophrenia patients. Additionally, the serum levels of IL‐6 and IL‐1β were significantly higher in schizophrenia patients characterized by negative symptoms (negative group, n = 37) than in those characterized by positive symptoms (positive group, n = 46). Based on multivariate regression analyses, serum levels of IL‐1β were positively associated with the Negative Symptom subscore of the Positive and Negative Syndrome Scale in the negative group and in all patients with schizophrenia. Conclusion The two subtypes of schizophrenia may have different pathological mechanisms. Patients characterized by negative symptoms probably have more serious disturbances in neuroimmunology.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Different serum protein factor levels in first‐episode drug‐naive patients with schizophrenia characterized by positive and negative symptoms

Dai

Jie

Duan³

et al. 2020

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…Moreover, they reported an increase in Nerve Growth Factor (NGF) and Neurotrophin 3 levels. Such changes were associated with a significant clinical improvement of PANSS scoring as well as of social and occupational functionality [ 168 ]. In addition, a recent pharmacogenomic study was able to demonstrate that synapse-related genes are strong predictors for the clinical response to the AAPD lurasidone [ 169 ].…”

Section: Atypical Antipsychotic Drugs and Stress-related Mechanismmentioning

confidence: 99%

Anti-stress Properties of Atypical Antipsychotics

Sanson

Riva

2020

Pharmaceuticals

View full text Add to dashboard Cite

Stress exposure represents a major environmental risk factor for schizophrenia and other psychiatric disorders, as it plays a pivotal role in the etiology as well as in the manifestation of disease symptomatology. It may be inferred that pharmacological treatments must be able to modulate the behavioral, functional, and molecular alterations produced by stress exposure to achieve significant clinical outcomes. This review aims at examining existing clinical and preclinical evidence that supports the ability of atypical antipsychotic drugs (AAPDs) to modulate stress-related alterations. Indeed, while the pharmacodynamic differences between AAPDs have been extensively characterized, less is known on their ability to regulate downstream mechanisms that are critical for functional recovery and patient stabilization. We will discuss stress-related mechanisms, spanning from neuroendocrine function to inflammation and neuronal plasticity, which are relevant for the manifestation of schizophrenic symptomatology, and we will discuss if and how AAPDs may interfere with such mechanisms. Considering the impact of stress in everyday life, we believe that a better understanding of the potential effects of AAPDs on stress-related mechanisms may provide novel and important insights for improving therapeutic strategies aimed at promoting coping mechanisms and enhancing the quality of life of patients affected by psychiatric disorders.

show abstract

“…We further assessed 15 full-text publications and excluded five trials, including two flexible-dose trials 27,28 , one 3-week trial 29 , one trial in adolescent patients 30 , and one trial in adults with treatment-resistant schizophrenia 31 . Finally, ten RCTs were included for network meta-analysis [6][7][8][9][32][33][34][35][36][37] .…”

Section: Resultsmentioning

confidence: 99%

A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia

Srisurapanont

Suttajit

Likhitsathian

et al. 2021

Sci Rep

View full text Add to dashboard Cite

We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone in adults with acute schizophrenia. Different doses of lurasidone, other antipsychotics, and placebo were considered as independent treatments. Apart from all-cause dropout rates, four therapeutic and four adverse outcomes were included in the frequentist network meta-analysis (NMA). Lurasidone 160, 120, 80, 40, and 20 mg/day were studied in ten trials of 3,366 adults with schizophrenia exacerbation. Lurasidone 160 mg/day reduced Positive and Negative Syndrome Scale (PANSS) total scores significantly more than lurasidone 120, 80, 40, and 20 mg/day (mean differences = − 7.63, − 7.04, − 8.83, and − 12.25, respectively). All-cause dropout rates were significantly lower in participants receiving lurasidone 160 mg/day and 80 mg/day compared with those taking placebo. The half-maximal effective doses of lurasidone for PANSS total, PANSS positive, and MADRS score reductions were higher than 80 mg/day. The confidence of all NMA estimates was low or very low. Lurasidone 160 mg/day is currently the most efficacious and acceptable dose for acute schizophrenia. Its maximal effective doses may be higher than 160 mg/day.

show abstract

Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial

Cited by 20 publications

References 42 publications

Different serum protein factor levels in first‐episode drug‐naive patients with schizophrenia characterized by positive and negative symptoms

Different serum protein factor levels in first‐episode drug‐naive patients with schizophrenia characterized by positive and negative symptoms

Anti-stress Properties of Atypical Antipsychotics

A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia

Contact Info

Product

Resources

About